Q&A: Cure CMD’s Executive Director, Rachel Alvarez, gives in-depth insight into what to expect at the 2025 SciFam Conference.

Click the button at the bottom of the page to mail your representative now! On April 1, the U.S. Department of Health and Human Services...

CMD Advocates gathered in Washington, DC to honor, celebrate & champion for those living with rare disease.

CMD Community Member, Justin Moy, shares his journey with LAMA2-related muscular dystrophy and his life quest to cure his own condition.

The Cure CMD Legislative Advocacy team, along with our advocacy partners, continue to actively monitor developments and will provide updates

The meeting to kick off a project to publish CMD subtype-specific care guidelines was a great success.

Cure CMD Receives 2024 MDA Advocacy Collaboration Grant

Advocacy Advisory Council defines legislative priorities based on CMD Community survey results.

CMD affected individuals are given the opportunity to visit overseas through a foreign exchange arranged by community members.

Modalis Therapeutics program for LAMA2-RD gene therapy granted Rare Pediatric Disease Designation by FDA.

We are honored to support groundbreaking discoveries related to LMNA-CMD.

We are thrilled to announce a new clinical workshop focused on establishing CMD subtype-specific care recommendations.